Titan Pharmaceuticals Stock

TTNP

US8883147055

Real-time Estimate Cboe BZX Other stock markets 18:17:19 13/07/2026 +04			5-day change	1st Jan Change
0.7760 ^USD	+1.78%		+3.00%	-82.79%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.36M 4.95M 4.57M 8.67M 585M 8.82M 59.12M 23.21M 288M 23.03M 22.52M 991M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.89M 2.66M 2.46M 4.67M 315M 4.75M 31.82M 12.5M 155M 12.4M 12.13M 533M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news : Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	TITAN PHARMACEUTICALS : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
13/07/26	$0.7936	+4.09%	2,252
10/07/26	$0.7624	-5.01%	15,057
09/07/26	$0.8026	-0.06%	13,629
08/07/26	$0.8031	+6.09%	44,934
07/07/26	$0.7570	+0.62%	15,404

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

1 year	0.76	5.35
3 years	0	14.8
5 years	0	47.6
10 years	0	23,040.03

	2023	2024
Net sales	184K 161K 148K 137K 260K 17.55M 265K 1.77M 697K 8.65M 691K 676K 29.72M	-
Net income	-5.57M -4.87M -4.49M -4.15M -7.87M -531M -8.01M -53.68M -21.08M -262M -20.91M -20.45M -900M	-4.71M -4.12M -3.8M -3.51M -6.65M -449M -6.77M -45.37M -17.82M -221M -17.67M -17.29M -760M
Net Debt	-6.2M -5.42M -5M -4.62M -8.76M -591M -8.91M -59.72M -23.45M -291M -23.26M -22.75M -1B	-2.83M -2.48M -2.28M -2.11M -4M -270M -4.07M -27.29M -10.72M -133M -10.63M -10.4M -457M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news : Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Course Extremes

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.78%
Current month	-82.79%
Current year	-82.79%